What is Ginkgo Bioworks Holdings Inc's earnings per share (EPS)?

Ginkgo Bioworks Holdings Inc (DNA) reported diluted earnings per share of $-5.64 for fiscal year 2025. This represents a -53614.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Ginkgo Bioworks Holdings Inc Financials

DNA

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Ginkgo Bioworks Holdings Inc (DNA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DNA FY2025 2026-05-07

FY2025’s dominant mechanic was shrinking cash burn by cutting R&D and overhead faster than revenue declined.

$167M of cash was roughly equal to FY2025 operating cash burn of -$171M. That means the 4.9x current ratio says more about light near-term liabilities than about surplus funding; on the balance sheet this looks liquid, but the operating model is no longer carrying a large cash cushion.

By FY2025, revenue had fallen for a second straight year to $170M even as operating loss narrowed to -$315M, showing the company is being resized faster than commercial activity is shrinking. This is cost-base compression: lower overhead and research intensity are reducing losses, but they do not yet show a revenue engine reaching self-supporting scale.

R&D spending of $244M still exceeded revenue of $170M, which keeps the company in a development-stage posture despite smaller losses. Free cash flow improved because investment demands were also pulled back, so recent cash preservation came from doing less as well as spending less on the core operation.

Financial Health Signals

Financial Health Score 52/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Ginkgo Bioworks Holdings Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

-7.44

Ginkgo Bioworks Holdings Inc scores -7.44, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($635.6M) relative to total liabilities ($611.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

1/7

Ginkgo Bioworks Holdings Inc passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

546.51x

For every $1 of reported earnings, Ginkgo Bioworks Holdings Inc generates $546.51 in operating cash flow (-$171.1M OCF vs -$313K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$170.2M

YoY-25.1%

5Y CAGR+17.3%

Ginkgo Bioworks Holdings Inc generated $170.2M in revenue in fiscal year 2025. This represents a decrease of 25.1% from the prior year.

EBITDA

-$256.3M

YoY+48.4%

Ginkgo Bioworks Holdings Inc's EBITDA was -$256.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 48.4% from the prior year.

Net Income

-$313K

YoY+42.8%

Ginkgo Bioworks Holdings Inc reported -$313K in net income in fiscal year 2025. This represents an increase of 42.8% from the prior year.

EPS (Diluted)

$-5.64

YoY-53614.3%

Ginkgo Bioworks Holdings Inc earned $-5.64 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 53614.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$178.7M

YoY+53.2%

Ginkgo Bioworks Holdings Inc generated -$178.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 53.2% from the prior year.

Cash & Debt

$167.2M

YoY-70.2%

5Y CAGR-15.2%

Ginkgo Bioworks Holdings Inc held $167.2M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

58M

YoY+7.1%

Ginkgo Bioworks Holdings Inc had 58M shares outstanding in fiscal year 2025. This represents an increase of 7.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-185.3%

YoY+61.2pp

5Y CAGR-6.5pp

Ginkgo Bioworks Holdings Inc's operating margin was -185.3% in fiscal year 2025, reflecting core business profitability. This is up 61.2 percentage points from the prior year.

Net Margin

-0.2%

YoY+0.1pp

5Y CAGR+165.0pp

Ginkgo Bioworks Holdings Inc's net profit margin was -0.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 0.1 percentage points from the prior year.

Return on Equity

-0.1%

YoY+0.0pp

5Y CAGR+27.4pp

Ginkgo Bioworks Holdings Inc's ROE was -0.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 0.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$243.8M

YoY-42.5%

5Y CAGR+8.8%

Ginkgo Bioworks Holdings Inc invested $243.8M in research and development in fiscal year 2025. This represents a decrease of 42.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$7.7M

YoY-87.7%

5Y CAGR-33.2%

Ginkgo Bioworks Holdings Inc invested $7.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 87.7% from the prior year.

DNA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$170.2M-25.1%	$227.0M-9.7%	$251.5M-47.4%	$477.7M+52.2%	$313.8M+309.4%	$76.7M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$243.8M-42.5%	$424.1M-27.0%	$580.6M-44.8%	$1.1B-8.4%	$1.1B+619.6%	$159.8M
SG&A Expenses	$183.3M-25.5%	$246.2M-36.1%	$385.0M-73.1%	$1.4B+65.7%	$863.0M+2152.8%	$38.3M
Operating Income	-$315.3M+43.7%	-$559.8M+35.2%	-$864.4M+60.9%	-$2.2B-20.8%	-$1.8B-1234.4%	-$137.0M
Interest Expense	$0-100.0%	$94K+1.1%	$93K-12.3%	$106K-95.5%	$2.4M-0.5%	$2.4M
Income Tax	-$837K-74.7%	-$479K-574.6%	-$71K+99.5%	-$15.0M-915.3%	-$1.5M-178.3%	$1.9M
Net Income	-$313K+42.8%	-$547K+38.7%	-$893K+57.6%	-$2.1M-15.0%	-$1.8M+98.6%	-$126.6M
EPS (Diluted)	$-5.64-53614.3%	$-0.01+42.9%	$-0.02	$-0.05+96.4%	$-1.39-1290.0%	$-0.10

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$19.5M-55.2%	$43.5M+12.0%	$38.8M-21.7%	$49.6M+29.8%	$38.2M-12.8%	$43.8M-50.8%	$89.0M+58.4%	$56.2M
Cost of Revenue	$3.1M	N/A	N/A	N/A	$4.1M	N/A	N/A	N/A
Gross Profit	$16.4M	N/A	N/A	N/A	$34.1M	N/A	N/A	N/A
R&D Expenses	$49.9M-0.4%	$50.1M-27.7%	$69.4M+29.9%	$53.4M-24.7%	$70.9M-7.1%	$76.4M-0.8%	$77.0M-42.6%	$134.2M
SG&A Expenses	$37.8M-31.6%	$55.3M+23.1%	$45.0M+3.9%	$43.3M+9.0%	$39.7M-30.7%	$57.3M+9.6%	$52.3M-21.1%	$66.3M
Operating Income	-$71.4M+9.4%	-$78.7M+12.5%	-$90.0M-37.3%	-$65.5M+19.1%	-$81.0M+21.8%	-$103.6M-87.7%	-$55.2M+75.2%	-$222.9M
Interest Expense	$3.6M+120.1%	-$17.9M-411.8%	$5.7M-5.6%	$6.1M0.0%	$6.1M-23.5%	$7.9M+185.9%	-$9.3M+10.3%	-$10.3M
Income Tax	-$80K+87.6%	-$643K-64400.0%	$1K+100.4%	-$283K-421.6%	$88K+127.1%	-$325K+13.3%	-$375K-297.4%	$190K
Net Income	-$82.6M-135.6%	$231.7M+386.9%	-$80.8M-33.9%	-$60.3M+33.7%	-$91.0M-120.7%	$438.9M+878.2%	-$56.4M+74.0%	-$217.2M
EPS (Diluted)	N/A	N/A	$-1.45-31.8%	$-1.10+34.5%	$-1.68	N/A	$-1.08	$-4.23

DNA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.1B-18.7%	$1.4B-17.3%	$1.7B-34.4%	$2.5B+22.6%	$2.1B+206.7%	$675.2M
Current Assets	$471.8M-21.7%	$602.7M-39.8%	$1.0B-30.9%	$1.5B-15.8%	$1.7B+304.0%	$426.5M
Cash & Equivalents	$167.2M-70.2%	$561.6M-40.5%	$944.1M-28.3%	$1.3B-15.1%	$1.6B+307.0%	$380.8M
Inventory	N/A	N/A	$46K-98.9%	$4.4M+29.8%	$3.4M+22.9%	$2.7M
Accounts Receivable	$24.0M+9.9%	$21.9M+27.4%	$17.2M-78.8%	$80.9M-38.5%	$131.5M+688.0%	$16.7M
Goodwill	N/A	$0-100.0%	$49.2M-18.2%	$60.2M+182.5%	$21.3M+1047.7%	$1.9M
Total Liabilities	$611.1M-7.6%	$661.4M+16.4%	$568.2M-29.2%	$803.0M+59.5%	$503.6M+145.5%	$205.1M
Current Liabilities	$96.0M-10.5%	$107.3M-34.5%	$163.9M-5.3%	$173.0M+28.3%	$134.8M+84.0%	$73.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$508.6M-29.0%	$716.1M-34.7%	$1.1B-36.8%	$1.7B+15.3%	$1.5B+226.3%	$461.4M
Retained Earnings	-$6.2B-5.4%	-$5.8B-10.3%	-$5.3B-20.3%	-$4.4B-91.4%	-$2.3B-391.1%	-$467.9M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$1.0B-7.7%	$1.1B-5.8%	$1.2B-3.4%	$1.2B-4.8%	$1.3B-6.1%	$1.4B-7.0%	$1.5B-8.9%	$1.6B
Current Assets	$410.0M-13.1%	$471.8M-6.8%	$506.1M-3.2%	$523.0M-7.4%	$564.5M-6.3%	$602.7M-9.0%	$662.5M-15.4%	$783.4M
Cash & Equivalents	$143.9M-14.0%	$167.2M+50.5%	$111.1M-45.4%	$203.6M-34.8%	$312.4M-44.4%	$561.6M-8.9%	$616.2M-15.6%	$730.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$19.8M-17.5%	$24.0M+12.1%	$21.4M-3.3%	$22.2M-15.7%	$26.3M+20.3%	$21.9M-6.6%	$23.4M+25.9%	$18.6M
Goodwill	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
Total Liabilities	$589.9M-3.5%	$611.1M-2.9%	$629.4M+1.8%	$618.1M-4.3%	$646.0M-2.3%	$661.4M-3.2%	$682.9M-13.8%	$792.2M
Current Liabilities	$79.6M-17.1%	$96.0M-16.8%	$115.3M+19.2%	$96.7M-16.4%	$115.7M+7.8%	$107.3M-6.3%	$114.4M-31.1%	$166.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$443.2M-12.9%	$508.6M-9.1%	$559.8M-8.7%	$613.0M-5.3%	$647.4M-9.6%	$716.1M-10.3%	$797.9M-4.2%	$833.1M
Retained Earnings	-$6.2B-1.3%	-$6.2B-1.3%	-$6.1B-1.3%	-$6.0B-1.0%	-$5.9B-1.6%	-$5.8B-1.9%	-$5.7B-1.0%	-$5.7B

DNA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$171.1M+46.5%	-$319.6M-8.2%	-$295.5M-17.2%	-$252.2M+0.6%	-$253.8M-86.9%	-$135.8M
Capital Expenditures	$7.7M-87.7%	$62.5M+53.3%	$40.8M-21.9%	$52.3M-7.5%	$56.5M-2.2%	$57.8M
Free Cash Flow	-$178.7M+53.2%	-$382.1M-13.6%	-$336.3M-10.5%	-$304.5M+1.9%	-$310.3M-60.3%	-$193.7M
Investing Cash Flow	-$240.3M-286.1%	-$62.2M+22.9%	-$80.7M-19.7%	-$67.4M+8.0%	-$73.3M-9.1%	-$67.1M
Financing Cash Flow	$17.8M+1122.1%	-$1.7M+45.9%	-$3.2M-103.4%	$95.3M-93.8%	$1.5B+1598.6%	$90.3M
Dividends Paid	$0	$0	$0	$0	$0	N/A
Share Buybacks	N/A	N/A	$0	$0-100.0%	$25.0M	$0

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$46.7M+2.1%	-$47.7M-50.9%	-$31.6M+21.5%	-$40.3M+21.9%	-$51.5M-21.4%	-$42.4M+59.0%	-$103.5M-22.6%	-$84.4M
Capital Expenditures	$1.9M+38560.0%	$5K	$0-100.0%	$38K-99.5%	$7.6M-44.4%	$13.7M-9.1%	$15.1M-44.2%	$27.0M
Free Cash Flow	-$48.6M-2.0%	-$47.7M-50.9%	-$31.6M+21.6%	-$40.3M+31.9%	-$59.1M-5.3%	-$56.1M+52.7%	-$118.6M-6.4%	-$111.4M
Investing Cash Flow	$23.1M-75.7%	$95.1M+230.6%	-$72.8M-14.0%	-$63.9M+67.8%	-$198.7M-1418.4%	-$13.1M-28.3%	-$10.2M+62.0%	-$26.8M
Financing Cash Flow	-$19K-100.2%	$8.1M-18.1%	$9.9M+10240.8%	-$98K+52.7%	-$207K-2.0%	-$203K+56.3%	-$465K-105.8%	-$226K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

DNA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-185.3%+61.2pp	-246.5%+97.2pp	-343.8%+118.7pp	-462.4%+120.2pp	-582.6%-403.9pp	-178.8%
Net Margin	-0.2%+0.1pp	-0.2%+0.1pp	-0.4%+0.1pp	-0.4%+0.1pp	-0.6%+164.6pp	-165.2%
Return on Equity	-0.1%+0.0pp	-0.1%0.0pp	-0.1%+0.0pp	-0.1%0.0pp	-0.1%+27.3pp	-27.4%
Return on Assets	-0.0%+0.0pp	-0.0%0.0pp	-0.1%+0.0pp	-0.1%0.0pp	-0.1%+18.7pp	-18.8%
Current Ratio	4.92-0.7	5.62-0.5	6.11-2.3	8.38-4.4	12.79+7.0	5.83
Debt-to-Equity	1.20+0.3	0.92+0.4	0.52+0.1	0.46+0.1	0.33-0.1	0.44
FCF Margin	-105.0%+63.3pp	-168.3%-34.6pp	-133.7%-70.0pp	-63.7%+35.2pp	-98.9%+153.7pp	-252.6%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	84.1%	N/A	N/A	N/A	89.3%	N/A	N/A	N/A
Operating Margin	-366.5%-185.4pp	-181.1%+50.7pp	-231.8%-99.7pp	-132.1%+79.7pp	-211.8%+24.5pp	-236.3%-174.3pp	-62.0%+334.7pp	-396.7%
Net Margin	-424.1%-956.9pp	532.8%+740.8pp	-207.9%-86.4pp	-121.6%+116.4pp	-237.9%-1239.0pp	1001.1%+1064.4pp	-63.3%+323.1pp	-386.4%
Return on Equity	-18.6%-64.2pp	45.6%+60.0pp	-14.4%-4.6pp	-9.8%+4.2pp	-14.1%-75.4pp	61.3%+68.4pp	-7.1%+19.0pp	-26.1%
Return on Assets	-8.0%-28.7pp	20.7%+27.5pp	-6.8%-1.9pp	-4.9%+2.1pp	-7.0%-38.9pp	31.9%+35.7pp	-3.8%+9.6pp	-13.4%
Current Ratio	5.15+0.2	4.92+0.5	4.39-1.0	5.41+0.5	4.88-0.7	5.62-0.2	5.79+1.1	4.71
Debt-to-Equity	1.33+0.1	1.20+0.1	1.12+0.1	1.01+0.0	1.00+0.1	0.92+0.1	0.86-0.1	0.95
FCF Margin	-249.7%-140.0pp	-109.7%-28.3pp	-81.4%-0.1pp	-81.2%+73.5pp	-154.7%-26.6pp	-128.1%+5.1pp	-133.2%+65.1pp	-198.2%

Similar Companies

Anaptysbio Inc ANAB

$1.9B

Meiragtx Holdings Plc MGTX

$1.3B

Xencor XNCR

$1.2B

Septerna, Inc. SEPN

$1.6B

Keros Therapeutics, Inc. KROS

$231.0M

Frequently Asked Questions

What is Ginkgo Bioworks Holdings Inc's annual revenue?

Ginkgo Bioworks Holdings Inc (DNA) reported $170.2M in total revenue for fiscal year 2025. This represents a -25.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Ginkgo Bioworks Holdings Inc's revenue growing?

Ginkgo Bioworks Holdings Inc (DNA) revenue declined by 25.1% year-over-year, from $227.0M to $170.2M in fiscal year 2025.

Is Ginkgo Bioworks Holdings Inc profitable?

No, Ginkgo Bioworks Holdings Inc (DNA) reported a net income of -$313K in fiscal year 2025, with a net profit margin of -0.2%.

What is Ginkgo Bioworks Holdings Inc's EBITDA?

Ginkgo Bioworks Holdings Inc (DNA) had EBITDA of -$256.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Ginkgo Bioworks Holdings Inc's operating margin?

Ginkgo Bioworks Holdings Inc (DNA) had an operating margin of -185.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Ginkgo Bioworks Holdings Inc's net profit margin?

Ginkgo Bioworks Holdings Inc (DNA) had a net profit margin of -0.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Ginkgo Bioworks Holdings Inc's return on equity (ROE)?

Ginkgo Bioworks Holdings Inc (DNA) has a return on equity of -0.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Ginkgo Bioworks Holdings Inc's free cash flow?

Ginkgo Bioworks Holdings Inc (DNA) generated -$178.7M in free cash flow during fiscal year 2025. This represents a 53.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Ginkgo Bioworks Holdings Inc's operating cash flow?

Ginkgo Bioworks Holdings Inc (DNA) generated -$171.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Ginkgo Bioworks Holdings Inc's total assets?

Ginkgo Bioworks Holdings Inc (DNA) had $1.1B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Ginkgo Bioworks Holdings Inc's capital expenditures?

Ginkgo Bioworks Holdings Inc (DNA) invested $7.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Ginkgo Bioworks Holdings Inc spend on research and development?

Ginkgo Bioworks Holdings Inc (DNA) invested $243.8M in research and development during fiscal year 2025.

How many shares does Ginkgo Bioworks Holdings Inc have outstanding?

Ginkgo Bioworks Holdings Inc (DNA) had 58M shares outstanding as of fiscal year 2025.

What is Ginkgo Bioworks Holdings Inc's current ratio?

Ginkgo Bioworks Holdings Inc (DNA) had a current ratio of 4.92 as of fiscal year 2025, which is generally considered healthy.

What is Ginkgo Bioworks Holdings Inc's debt-to-equity ratio?

Ginkgo Bioworks Holdings Inc (DNA) had a debt-to-equity ratio of 1.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Ginkgo Bioworks Holdings Inc's return on assets (ROA)?

Ginkgo Bioworks Holdings Inc (DNA) had a return on assets of -0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Ginkgo Bioworks Holdings Inc's cash runway?

Based on fiscal year 2025 data, Ginkgo Bioworks Holdings Inc (DNA) had $167.2M in cash against an annual operating cash burn of $171.1M. This gives an estimated cash runway of approximately 12 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Ginkgo Bioworks Holdings Inc's Altman Z-Score?

Ginkgo Bioworks Holdings Inc (DNA) has an Altman Z-Score of -7.44, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Ginkgo Bioworks Holdings Inc's Piotroski F-Score?

Ginkgo Bioworks Holdings Inc (DNA) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Ginkgo Bioworks Holdings Inc's earnings high quality?

Ginkgo Bioworks Holdings Inc (DNA) has an earnings quality ratio of 546.51x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Ginkgo Bioworks Holdings Inc?

Ginkgo Bioworks Holdings Inc (DNA) scores 52 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.